{"disease":{"id":"fumarate-hydratase-deficient-renal-cell-carcinoma","name":"fumarate hydratase deficient renal cell carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04623502","title":"An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT04068831","title":"Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT05877820","title":"A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"RenJi Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}